Salvage therapy after failure from anti-PD-1 single agent treatment: A Study by the German ADOReg melanoma registry.
Michael Weichenthal(Christian-Albrechts-Universität zu Kiel), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Rudolf Herbst(Helios Klinikum Erfurt), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), I. Feldmann-Böddeker(Klinikum Chemnitz), Claudia Pföhler(Saarland University), Sebastian Haferkamp(University Hospital Regensburg), Katharina C. Kähler(Christian-Albrechts-Universität zu Kiel), Dirk Schadendorf(National Center for Tumor Diseases), Friedegund Meier(National Center for Tumor Diseases), Julia Welzel(University Hospital Augsburg), Selma Ugurel(Klinikum Bielefeld), Alexander Kreuter(HELIOS St. Elisabeth Klinik Oberhausen), Ulrike Leiter(University of Tübingen), Imke Satzger(Medizinische Hochschule Hannover), Patrick Terheyden(University Hospital Schleswig-Holstein), Jens Ulrich, Jochen Utikal(German Cancer Research Center)
Cited by 26
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k